Literature Cited

  • 1
    Pegram MD,Konecny G,Slamon DJ. The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (Trastuzumab) therapy for breast cancer. Cancer Treat Res 2000; 103: 5775.
  • 2
    Pegram M,Slamon D. Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy. Semin Oncol 2000; 27: 1319.
  • 3
    Brockhoff G,Heckel B,Schmidt-Bruecken E,Plander M,Hofstaedter F,Vollmann A,Diermeier S. Differential impact of Cetuximab, Pertuzumab and Trastuzumab on BT474 and SK-BR-3 breast cancer cell proliferation. Cell Prolif 2007; 40: 488507.
  • 4
    Nahta R,Esteva FJ. In vitro effects of Trastuzumab and vinorelbine in Trastuzumab-resistant breast cancer cells. Cancer Chemother Pharmacol 2004; 53: 186190.
  • 5
    Campoli M,Ferris R,Ferrone S,Wang X. Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies. Clin Cancer Res 2010; 16: 1120.
  • 6
    Reichert JM,Rosensweig CJ,Faden LB,Dewitz MC. Monoclonal antibody successes in the clinic. Nat Biotechnol 2005; 23: 10731078.
  • 7
    Brockhoff G,Heiss P,Schlegel J,Hofstaedter F,Knuechel R. Epidermal growth factor receptor, c-erbB2 and c-erbB3 receptor interaction, and related cell cycle kinetics of SK-BR-3 and BT474 breast carcinoma cells. Cytometry 2001; 44: 338348.
  • 8
    Diermeier S,Horváth G,Knuechel-Clarke R,Hofstaedter F,Szöllosi J,Brockhoff G. Epidermal growth factor receptor coexpression modulates susceptibility to herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation. Exp Cell Res 2005; 304: 604619.
  • 9
    Barok M,Balazs M,Lazar V,Rakosy Z,Toth E,Treszl A,Vereb G,Colbern GT,Park JW,Szollosi J. Characterization of a novel, Trastuzumab resistant human breast cancer cell line. Front Biosci (Elite Ed) 2010; 2: 627640.
  • 10
    Tanner M,Kapanen AI,Junttila T,Raheem O,Grenman S,Elo J,Elenius K,Isola J. Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer. Mol Cancer Ther 2004; 3: 15851592.
  • 11
    Pohlmann PR,Mayer IA,Mernaugh R. Resistance to Trastuzumab in breast cancer. Clin Cancer Res 2009; 15: 74797491.
  • 12
    Konecny GE,Pegram MD,Venkatesan N,Finn R,Yang G,Rahmeh M,Untch M,Rusnak DW,Spehar G,Mullin RJ, et al. Activity of the dual kinase inhibitor Lapatinib (GW572016) against HER-2-overexpressing and Trastuzumab-treated breast cancer cells. Cancer Res 2006; 66: 16301639.
  • 13
    Foster FM,Owens TW,Tanianis-Hughes J,Clarke RB,Brennan K,Bundred NJ,Streuli CH. Targeting inhibitor of apoptosis proteins in combination with ErbB antagonists in breast cancer. Breast Cancer Res 2009; 11: R41.
  • 14
    Weigelt B,Lo AT,Park CC,Gray JW,Bissell MJ. HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment. Breast Cancer Res Treat 2010; 122: 3543.
  • 15
    Scaltriti M,Verma C,Guzman M,Jimenez J,Parra JL,Pedersen K,Smith DJ,Landolfi S,Ramon y Cajal S,Arribas J, et al. Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates Trastuzumab-dependentcell cytotoxicity. Oncogene 2009; 28: 803814.
  • 16
    Giampaglia M,Chiuri VE,Tinelli A,De Laurentiis M,Silvestris N,Lorusso V. Lapatinib in breast cancer: Clinical experiences and future perspectives. Cancer Treat Rev 2010; 36: S72S79.
  • 17
    Macfarlane RJ,Gelmon KA. Lapatinib for breast cancer: A review of the current literature. Expert Opin Drug Saf 2011; 10: 109121.
  • 18
    Badache A,Hynes NE. A new therapeutic antibody masks ErbB2 to its partners. Cancer Cell 2004; 5: 299301.
  • 19
    Diermeier-Daucher S,Hasmann M,Brockhoff G. Flow cytometric FRET analysis of erbB receptor interaction on a cell-by-cell basis. Ann NY Acad Sci 2008; 1130: 280286.
  • 20
    Wood ER,Truesdale AT,McDonald OB,Yuan D,Hassell A,Dickerson SH,Ellis B,Pennisi C,Horne E,Lackey K, et al. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): Relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 2004; 64: 66526659.
  • 21
    Reid A,Vidal L,Shaw H,de Bono J. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). Eur J Cancer 2007; 43: 481489.
  • 22
    Révillion F,Lhotellier V,Hornez L,Bonneterre J,Peyrat JP. ErbB/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis. Ann Oncol 2008; 19: 7380.
  • 23
    McIntyre E,Blackburn E,Brown PJ,Johnson CG,Gullick WJ. The complete family of epidermal growth factor receptors and their ligands are co-ordinately expressed in breast cancer. Breast Cancer Res Treat 2010; 122: 105110.
  • 24
    Brockhoff G. DNA and proliferation analysis in flow cytometry. In: SackU,TárnokA,RotheG, editors. Cellular Diagnostics—Basic Principles, Methods and Clinical Applications of Flow Cytometry. Freiburg, Germany: Karber; 2008. pp 390425.
  • 25
    Rusnak DW,Lackey K,Affleck K,Wood ER,Alligood KJ,Rhodes N,Keith BR,Murray DM,Knight WB,Mullin RJ, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor. GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 2001; 1: 8594.
  • 26
    Xia W,Gerard CM,Liu L,Baudson NM,Ory TL,Spector NL. Combining Lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. Oncogene 2005; 24: 62136221.
  • 27
    O'Brien NA,Browne BC,Chow L,Wang Y,Ginther C,Arboleda J,Duffy MJ,Crown J,O'Donovan N,Slamon DJ. Activated phosphoinositide 3-kinase/AKT signaling confers resistance to Trastuzumab but not Lapatinib. Mol Cancer Ther 2010; 9: 14891502.
  • 28
    Dufner A,Thomas G. Ribosomal S6 kinase signaling and the control of translation. Exp Cell Res 1999; 253: 100109.
  • 29
    Silva CM. Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis. Oncogene 2004; 23: 80178023.
  • 30
    Motti ML,De Marco C,Califano D,Fusco A,Viglietto G. Akt-dependent T198 phosphorylation of cyclin-dependent kinase inhibitor p27kip1 in breast cancer. Cell Cycle 2004; 3: 10741080.
  • 31
    Larrea MD,Wander SA,Slingerland JM. p27 as Jekyll and Hyde: Regulation of cell cycle and cell motility. Cell Cycle 2009; 8: 34553461.
  • 32
    D'Alessio A,De Luca A,Maiello MR,Lamura L,Rachiglio AM,Napolitano M,Gallo M,Normanno N. Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells. Breast Cancer Res Treat 2010; 123: 387396.
  • 33
    Zhu H,Zhang G,Wang Y,Xu N,He S,Zhang W,Chen M,Liu M,Quan L,Bai J, et al. Inhibition of ErbB2 by Herceptin reduces survivin expression via the ErbB2-β-catenin/TCF4-survivin pathway in ErbB2-overexpressed breast cancer cells. Cancer Sci 2010; 101: 11561162.
  • 34
    Ruchaud S,Carmena M,Earnshaw WC. Chromosomal passengers: Conducting cell division. Nat Rev Mol Cell Biol 2007; 8: 798812.
  • 35
    Stolz A,Ertych N,Bastians H. Tumor suppressor CHK2: Regulator of DNA damage response and mediator of chromosomal stability. Clin Cancer Res 2011; 17: 401405.
  • 36
    Flaherty KT,Puzanov I. Building on a foundation of VEGF and mTOR targeted agents in renal cell carcinoma. Biochem Pharmacol 2010; 80: 638646.
  • 37
    Hudziak RM,Lewis GD,Winget M,Fendly BM,Shepard HM,Ullrich A. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 1989; 9: 11651172.
  • 38
    Jones JT,Akita RW,Sliwkowski MX. Binding specificities and affinities of egf domains for ErbB receptors. FEBS Lett 1999; 447: 227231.
  • 39
    Graus-Porta D,Beerli RR,Daly JM,Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997; 16: 16471655.
  • 40
    Gaborit N,Larbouret C,Vallaghe J,Peyrusson F,Bascoul-Mollevi C,Crapez E,Azria D,Chardes T,Poul MA,Mathis G, et al. Time resolved fluorescence resonance energy transfer (TR-FRET) to analyze the disruption of EGFR/HER2 dimers: A new method to evaluate the efficiency of targeted therapy using monoclonal antibodies. J Biol Chem 2011; 286: 1133711345.
  • 41
    Hughes JB,Berger C,Rødland MS,Hasmann M,Stang E,Madshus IH. Pertuzumab increases epidermal growth factor receptor down-regulation by counteracting epidermal growth factor receptor-ErbB2 heterodimerization. Mol Cancer Ther 2009; 8: 18851892.
  • 42
    Agus DB,Akita RW,Fox WD,Lewis GD,Higgins B,Pisacane PI,Lofgren JA,Tindell C,Evans DP,Maiese K, et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002; 2: 127137.